Trust Point Inc. Sells 1,083 Shares of Enovis Co. (NYSE:ENOV)

Trust Point Inc. decreased its holdings in Enovis Co. (NYSE:ENOV) by 6.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,903 shares of the company’s stock after selling 1,083 shares during the quarter. Trust Point Inc.’s holdings in Enovis were worth $654,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. UMB Bank n.a. increased its stake in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after acquiring an additional 437 shares during the period. Pinnacle Bancorp Inc. grew its stake in shares of Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after purchasing an additional 300 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Enovis in the 3rd quarter worth approximately $55,000. FMR LLC lifted its position in shares of Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after buying an additional 484 shares during the period. Finally, Heritage Family Offices LLP acquired a new stake in Enovis in the 3rd quarter valued at $206,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Price Performance

Shares of ENOV stock opened at $46.14 on Wednesday. The stock’s fifty day moving average is $46.01 and its 200-day moving average is $44.50. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03. The stock has a market capitalization of $2.62 billion, a PE ratio of -21.07 and a beta of 1.94.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $505.22 million during the quarter, compared to analysts’ expectations of $504.44 million. During the same quarter last year, the company posted $0.56 EPS. The company’s quarterly revenue was up 21.0% compared to the same quarter last year. Equities research analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a “buy” rating and set a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $65.86.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.